🧾 What This Document Is

This is a Form 6-K, a report that foreign companies listed on U.S. exchanges (like Alpha Tau, based in Israel) file with the SEC to share material news with investors. This specific report contains a press release announcing a major milestone for their cancer therapy.

👉 In short: It's an official update from Alpha Tau to the market about promising clinical data being presented at a major medical conference.

🏢 What The Company Does

Alpha Tau Medical Ltd. is an Israeli oncology company. They developed a novel cancer treatment called Alpha DaRT®.

👉 In simple terms: They use tiny radioactive sources (using Radium-224) that are injected directly into a solid tumor. As these sources decay, they release alpha particles that are designed to destroy the tumor while sparing surrounding healthy tissue.

🧪 The Clinical Data & The Conference

This announcement is about their pancreatic cancer studies. A summary of results from two first-in-human trials conducted at Hadassah Medical Center in Jerusalem has been accepted for a major oral presentation at Digestive Disease Week (DDW) 2026.

Why it matters: DDW is the world's largest gastroenterology conference. Getting an oral presentation is a prestigious platform, signaling that the scientific community finds this data significant and novel. This is the first time their pancreatic cancer data has been selected for such a presentation at a major conference.
Key Details:
- Presentation Title: "Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials..."
- When: Saturday, May 2, 2026, at 10:30 AM (Central Time).
- Who is presenting: Dr. Harold Jacob, the study's Principal Investigator from Hadassah.

🚀 Key Moves & What They Signal

The company is strategically showcasing its data where it matters most—to gastroenterologists, who are often the first specialists to diagnose and treat pancreatic cancer.

Validation at a Top Forum: Presenting at DDW lends credibility and could accelerate awareness and future adoption of Alpha DaRT if the data is strong.
Targeting a Difficult Cancer: Pancreatic cancer has a poor prognosis, and most patients are inoperable at diagnosis. Alpha DaRT is positioned as a novel option for both locally advanced and metastatic cases.
Enabling New Delivery Methods: The technology is designed to be delivered via Endoscopic Ultrasound (EUS), a procedure gastroenterologists perform. This could put them "at the forefront of a new era" in treating this cancer.

📦 Financial & Business Position

While this press release doesn't contain financial figures, the announcement has clear business implications:

Pipeline Progress: This is a positive clinical development milestone for their key asset, Alpha DaRT, in a challenging cancer type.
Future Catalysts: The full data presentation in May 2026 will be a major event. The CEO and CMO both mentioned that these studies inform their ongoing IMPACT pilot study in the U.S. and plans for a future pivotal study.
Stock Tickers: The company trades on Nasdaq under DRTS (common shares) and DRTSW (warrants).

🔮 What's Next

The company's clinical path is becoming clearer:

Immediate Next Step: The full data presentation at DDW on May 2, 2026.
U.S. Expansion: Actively enrolling the IMPACT pilot study in the United States.
Strategic Goal: Working toward a larger pivotal study, which would be necessary for potential regulatory approval.

⚖️ The Big Picture: Strengths & Risks

👍 Strengths:

Novel Technology: Alpha DaRT uses a unique mechanism (alpha-emitting radionuclides) that is highly targeted.
Growing Clinical Validation: Oral presentation at a premier conference strengthens the scientific profile.
Strategic Clinical Path: They are building data in a high-need area (pancreatic cancer) and expanding into the critical U.S. market.

⚠️ Risks & Considerations:

Early Stage: These are "first-in-human" and pilot studies. Much larger trials are needed to prove efficacy and safety.
High-Risk Disease Area: Pancreatic cancer is notoriously difficult to treat, presenting a high bar for success.
Commercialization is Distant: This is purely clinical news; revenue from this application is a long-term prospect.

🌍 Industry Context

Pancreatic cancer has one of the lowest survival rates among cancers. Treatment options are limited, especially for advanced disease, creating a massive unmet medical need. Any new therapeutic approach that shows promise garners significant attention from researchers, doctors, and investors.

🧠 The Analogy

Think of Alpha DaRT like a precise, time-released therapy deployed inside the tumor itself. It's not like flooding the body with systemic chemo (a broad flood). Instead, it's like planting tiny, short-lived "energy mines" within the tumor that explode with alpha particles, destroying it from the inside out while trying to minimize damage to the neighborhood.

📇 Key Contacts & People

Uzi Sofer: CEO of Alpha Tau
Dr. Harold Jacob: Director of Advanced Gastrointestinal Endoscopy, Hadassah University Medical Center; Principal Investigator for the studies.
Dr. Robert Den: Chief Medical Officer of Alpha Tau
Investor Relations Contact: [email protected]

🧩 Final Takeaway

Alpha Tau is taking a significant step in validating its targeted radiation therapy in pancreatic cancer by earning a prestigious oral presentation at a top-tier medical conference. This increases visibility and provides a key data readout in 2026, marking important progress in their U.S. clinical development plan.

Alpha Tau Medical Ltd. — 6-K Filing